Drug Profile


Alternative Names: CI-1025; Vaprisol; YM-087

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Astellas Pharma
  • Developer Alliance Healthcare; Cumberland Pharmaceuticals; DB Pharm Korea; Piramal Critical Care
  • Class Benzazepines; Small molecules
  • Mechanism of Action Vasopressin 1 receptor antagonists; Vasopressin V2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hyponatraemia
  • Discontinued Heart failure

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 04 Apr 2016 Cumberland Pharmaceuticals and Clinigen enter into a licensing agreement to develop Vaprisol® (Cumberland Pharmaceuticals, Form 10-K, March 2016)
  • 14 Mar 2016 Cumberland Pharmaceuticals and Alliance Pharm PTE enter into a marketing license agreement for Vaprisol® in Singapore (Cumberland Pharmaceuticals, Form 10-K, March 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top